Show simple item record

dc.contributor.authorHague, Christina
dc.contributor.authorLogue, John P
dc.date.accessioned2016-06-24T11:23:39Z
dc.date.available2016-06-24T11:23:39Z
dc.date.issued2016-06en
dc.identifier.citationClinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases. 2016, 8 (3):175-80 Ther Adv Urolen
dc.identifier.issn1756-2872en
dc.identifier.pmid27247627en
dc.identifier.doi10.1177/1756287216629870en
dc.identifier.urihttp://hdl.handle.net/10541/614557
dc.description.abstractThe treatment of metastatic castrate-resistant prostate cancer (mCRPC) has grown over the past decade. The majority of patients develop bone metastases, which pose a significant burden on morbidity and mortality, especially skeletal-related events. Whilst demonstrating a favourable safety profile and improving symptoms, radiopharmaceuticals have until recently failed to show a survival benefit. However, since the large phase III randomized ALSYMPCA trial, the calcium mimetic properties of radium-223 (Ra223) have improved patients' quality of life and improved survival whilst keeping toxicities to a minimum. This review article summarizes the clinical data including our real life experience on the usage of the alpha emitter Ra223 in mCRPC, paying particular attention to how clinicians should best monitor response.
dc.language.isoenen
dc.rightsArchived with thanks to Therapeutic advances in urologyen
dc.titleClinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Wimslow Road, Manchester M20 4BXen
dc.identifier.journalTherapeutic Advances in Urologyen
html.description.abstractThe treatment of metastatic castrate-resistant prostate cancer (mCRPC) has grown over the past decade. The majority of patients develop bone metastases, which pose a significant burden on morbidity and mortality, especially skeletal-related events. Whilst demonstrating a favourable safety profile and improving symptoms, radiopharmaceuticals have until recently failed to show a survival benefit. However, since the large phase III randomized ALSYMPCA trial, the calcium mimetic properties of radium-223 (Ra223) have improved patients' quality of life and improved survival whilst keeping toxicities to a minimum. This review article summarizes the clinical data including our real life experience on the usage of the alpha emitter Ra223 in mCRPC, paying particular attention to how clinicians should best monitor response.


This item appears in the following Collection(s)

Show simple item record